• Announcements

    • Joelf

      Upgraded Sclero Forums!   05/18/2017

      Welcome to the Upgraded and Redesigned Sclero Forums!!   Our Forums are even better and more up to date than before.   Happy Posting to all our Members!!
janey

Safety, Tolerability and Pharmcodynamic Profile of Oral 2101 Once Daily for up to 14 Days in Secondary Raynaud's Disease

1 post in this topic

Safety, Tolerability and Pharmcodynamic Profile of Oral 2101 Once Daily for up to 14 Days in Secondary Raynaud's Disease.

 

To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period. Currently Recruiting. University des Saarlandes. Homburg, Germany. ClinicalTrials.gov. (Also see: Raynaud's)

 

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.


Janey Willis

ISN Support Specialist

(Retired) ISN Assistant Webmaster

(Retired) ISN News Director

(Retired) ISN Technical Writer for Training Manuals

International Scleroderma Network (ISN)

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!


Register a new account

Sign in

Already have an account? Sign in here.


Sign In Now